 Teva Pharmaceutical Industries Ltd NYSE:TEVA is down 2.1 at 8.54 at last check, after the company named former Novartis NVS and Biogen BIIB executive Richard Francis as its new chief executive officer, effective after the retirement of CEO Karen Schultz later this year. 